SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

PDL Biopharma, Inc. – ‘8-K’ for 2/2/05

On:  Friday, 2/4/05, at 4:45pm ET   ·   For:  2/2/05   ·   Accession #:  1275287-5-433   ·   File #:  0-19756

Previous ‘8-K’:  ‘8-K’ on 2/1/05 for 1/31/05   ·   Next:  ‘8-K’ on / for 2/7/05   ·   Latest:  ‘8-K’ on 12/14/20 for 12/11/20

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 2/04/05  PDL Biopharma, Inc.               8-K:8,9     2/02/05    2:16K                                    PR Newswire/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     14K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     10K 


8-K   —   Current Report

This is an HTML Document rendered as filed.  [ Alternative Formats ]

8-K1st “Page” of 3TOCTopPreviousNextBottomJust 1st
 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):
February 2, 2005

PROTEIN DESIGN LABS, INC.

(Exact name of registrant as specified in its charter)


Delaware

 

000-19756

 

94-3023969

(State or other jurisdiction of
incorporation)

 

(Commission File No.)

 

(I.R.S. Employer Identification
No.)


34801 Campus Drive

Fremont, California 94555

(Address of principal executive offices)

Registrant’s telephone number, including area code:
(510) 574-1400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



8-K2nd “Page” of 3TOC1stPreviousNextBottomJust 2nd

Item 8.01 Other Events.

          On February 2, 2005, Protein Design Labs, Inc. (“PDL”) issued a press release announcing a decision by the European Patent Office, Opposition Division, regarding PDL’s European antibody humanization patent EP 0 682 040.  A copy of PDL’s press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

          (c)     Exhibits.

Exhibit No.

 

Description


 


99.1

 

Press release issued by Protein Design Labs, Inc. on February 2, 2005.

2


8-KLast “Page” of 3TOC1stPreviousNextBottomJust 3rd

SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:   February 2, 2005

 

PROTEIN DESIGN LABS, INC.

 

 

 

 

By:

/s/ SERGIO GARCIA-RODRIGUEZ

 

 


 

 

Sergio Garcia-Rodriguez
Vice President, Legal, General Counsel and
Assistant Secretary

3



Dates Referenced Herein   and   Documents Incorporated by Reference

Referenced-On Page
This ‘8-K’ Filing    Date First  Last      Other Filings
Filed on:2/4/054
For Period End:2/2/05134
 List all Filings 
Top
Filing Submission 0001275287-05-000433   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 6:48:19.2am ET